Does atenolol differ from other beta-adrenergic blockers?

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• A recent meta-analysis suggested all beta-adrenergic blockers (B-blockers) are equally effective but less so than other antihypertensives.
• Published data indicate differing effects of atenolol versus non-atenolol B-blockers on mortality, arrhythmias, and post-myocardial infarction prognosis, favoring non-atenolol agents.
• The meta-analysis data suggested atenolol's lower efficacy compared to placebo and other antihypertensives, though not statistically significant.

Purpose of the Study:

• To re-evaluate the efficacy of beta-adrenergic blockers in hypertension treatment using a Bayesian approach.
• To determine if atenolol is representative of the broader class of beta-adrenergic blockers.
• To assess the clinical significance of differences in myocardial infarction risk between atenolol and non-atenolol beta-blockers.

Main Methods:

• Utilized a Bayesian statistical method for additional analysis of existing meta-analysis data.
• Performed comparative risk analysis for myocardial infarction in hypertensive patients.

Main Results:

• Hypertensive patients taking non-atenolol beta-blockers exhibited a statistically significant 13% lower risk of myocardial infarction (risk ratio 0.87; 90% credibility interval: 0.75–0.99) compared to those taking atenolol.
• The probability of a clinically relevant risk reduction (≥10%) with non-atenolol beta-blockers was 0.69.

Conclusions:

• The claim that all beta-adrenergic blockers are inferior antihypertensive drugs should be rejected.
• Atenolol is not representative of the beta-adrenergic blocker class; its use in comparisons with other antihypertensives is inappropriate.
• Non-atenolol beta-adrenergic blockers remain fundamental in antihypertensive therapy.